Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01313767
Other study ID # MT-PRT-ST01
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 2011
Est. completion date February 2012

Study information

Verified date March 2019
Source Medy-Tox
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a randomized, double blind, multi-center, active drug controlled, phase III clinical trial to compare the efficacy and safety of MEDITOXIN® versus BOTOX® in treatment of post stroke upper limb(wrist, finger, thumb) spasticity

Approximately 196 subjects(1:1 group ratio)will be enrolled. Subjects will receive a single treatment of intramuscular Investigational product up to 360U. The subjects will be observed every 4 weeks until 12 weeks post injection. Outcome measures include Modified Ashworth Scale (MAS), Disability Assessment Scale (DAS), Global Assessment Scale(patient or caregiver/investigator) and Carer burden scale. The primary efficacy endpoint is the change from baseline at week 4 for wrist flexor muscle tone as measured on the Modified Ashworth Scale. Safety parameters will also be measured including adverse events, vital signs and clinical laboratory tests (haematology, serum chemistry and urinanalysis).


Description:

Each completed subject will attend 4~5 clinic visits. The maximum study duration is 15 weeks. Only one upper limb (eligible inclusion/exclusion criteria) will be injected and evaluated in the study. Maximun injection dose is 360U.


Recruitment information / eligibility

Status Completed
Enrollment 196
Est. completion date February 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. Male or female patients = 20 years

2. = 6 weeks since the last stroke

3. = 2 points in the focal spasticity of wrist flexor and = 1 points at least one of elbow flexor and finger flexor as measured on MAS(0 to 4)

4. Targeted one functional disability item (i.e., hygiene, dressing, pain, or cosmesis) with a rating of 2 or greater on DAS (0 to 3)

5. Informed consent has been obtained.

Exclusion Criteria:

1. Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis

2. History(within 6 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb

3. History(within 6 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb

4. Fixed joint/muscle contracture

5. Severe atrophy

6. Concurrent treatment with an intrathecal baclofen

7. History(within 3 months of screening visit) Planned(during study period) treatment with Botulinum Toxin

8. Known allergy or sensitivity to study medication or its components

9. Concurrent or planed Muscle relaxants and/or benzodiazepine medication

- If patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed.

10. Current Physical, occupational, Splinting therapy

- If these therapy regimens will be permitted if they has been stable in the one month before screening;no treatment and no changes are planned during the study.

11. Patient who are participating in other clinical trials at the screening

12. Females who are pregnant, breatfeeding,or planning a pregnancy during the study period, or female of childbearing potential, not using a reliable means of centraception.

13. Patients who are not eligible for this study at the discretion of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Botulinum toxin type A
Botulinum toxin type A
Botulinum Toxin type A
Botulinum Toxin type A

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Medy-Tox

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary MAS(Modified Ashworth Scale) of Wrist Flexor Change from baseline at week 4 for wrist flexor muscle tone as measured on the MAS(Modified Ashworth Scale). The Modified Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Baseline and 4 weeks
Secondary MAS(Modified Ashworth Scale) of Wrist Flexor Change from baseline at week 8 and 12 for wrist flexor muscle tone as measured on the MAS(Modified Ashworth Scale).
The Modified Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).
Baseline, week 8 and week 12
Secondary MAS(Modified Ashworth Score) of Elbow Flexor Change from baseline at week 4, week 8 and 12 for elbow flexor muscle tone as measured on the MAS(Modified Ashworth Scale).
The Modified Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).
Baseline, week 4, week 8 and week 12
Secondary MAS(Modified Ashworth Score) of Finger Flexor Change from baseline at week 4, week 8 and 12 for finger flexor muscle tone as measured on the MAS(Modified Ashworth Scale).
The Modified Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).
Baseline, week 4, week 8 and week 12
Secondary MAS(Modified Ashworth Score) of Thumb Flexor Change from baseline at week 4, 8, 12 for thumb flexor muscle tone as measured on MAS.
The Modified Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).
Baseline, week 4, week 8 and week 12
Secondary Improvement Rate on the MAS(Modified Ashworth Score) of Wrist Flexor Improvement in the injected site muscle tone at week 4, 8 and 12 as measured by MAS(Modified Ashworth Score) of wrist flexor.
* A treatment response is defined as 1-point improvement on the MAS(Modified Ashworth Score) of injection site.
week 4, week 8, week 12
Secondary Improvement Rate on the MAS(Modified Ashworth Score) of Elbow Flexor Improvement in the injected site muscle tone at week 4, 8 and 12 as measured by MAS(Modified Ashworth Score) of elbow flexor.
* A treatment response is defined as 1-point improvement on the MAS(Modified Ashworth Score) of injection site
week 4, week 8, week 12
Secondary Improvement Rate on the MAS(Modified Ashworth Score) of Finger Flexor Improvement in the injected site muscle tone at week 4, 8 and 12 as measured by MAS(Modified Ashworth Score) of finger flexor.
* A treatment response is defined as 1-point improvement on the MAS(Modified Ashworth Score) of injection site.
week 4, week 8, week 12
Secondary Improvement Rate on the MAS(Modified Ashworth Score) of Thumb Flexor Improvement in the injected site muscle tone at week 4, 8 and 12 as measured by MAS(Modified Ashworth Score) of thumb flexor.
* A treatment response is defined as 1-point improvement on the MAS(Modified Ashworth Score) of injection site.
week 4, week 8, week 12
Secondary DAS(Disability Assessment Scale) of Hygiene Change From Baseline to week 4, 8, 12 in the DAS(Disability Assessment Scale) for the Principal Therapeutic Target as Hygiene.
The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).
Baseline, week 4, week 8 and week 12
Secondary DAS(Disability Assessment Scale) of Dressing Change From Baseline to week 4, 8, 12 in the DAS(Disability Assessment Scale) for the Principal Therapeutic Target as Dressing. The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). Baseline, week 4, week 8 and week 12
Secondary DAS(Disability Assessment Scale) of Limb Position Change From Baseline to week 4, 8, 12 in the DAS(Disability Assessment Scale) for the Principal Therapeutic Target as Limb Position.
The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).
Baseline, week 4, week 8 and week 12
Secondary DAS(Disability Assessment Scale) of Pain Change From Baseline to week 4, 8, 12 in the DAS(Disability Assessment Scale) for the Principal Therapeutic Target as Pain.
The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).
Baseline, week 4, week 8 and week 12
Secondary Global Assessment by Investigator Global assessment evaluated by investigator at week 12 after injection week 12
Secondary Global Assessment by Patient or Caregiver Global assessment evaluated by patient or caregiver at week 12 after injection week 12
Secondary Carer Burden Scale of Cleaning the Palm The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). Baseline, week 4, week 8 and week 12
Secondary Carer Burden Scale of Cutting the Finger-nails The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). Baseline, week 4, week 8 and week 12
Secondary Carer Burden Scale of Putting Shirts on The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). Baseline, week 4, week 8 and week 12
Secondary Carer Burden Scale of Cleaning the Armpit The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). Baseline, week 4, week 8 and week 12
See also
  Status Clinical Trial Phase
Recruiting NCT06150729 - Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
Completed NCT02400619 - Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Cross Over RCT Phase 1
Completed NCT02261142 - Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal TENS N/A
Completed NCT01945684 - A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity Phase 3
Completed NCT01444794 - Adult Subjects Suffering From Lower Limb Spasticity Following Stroke
Terminated NCT02877836 - Functional MRI and DTI in the Preoperative Assessment of Dystonia N/A
Completed NCT02334683 - Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia N/A
Completed NCT02170779 - Developing and Testing a Comprehensive MS Spasticity Management Program Phase 2
Recruiting NCT05674604 - Cryoneurolysis for Knee and Shoulder Pain in an Inpatient Setting
Not yet recruiting NCT05926596 - Leg Stretching Using an Exoskeleton on Demand for People With Spasticity N/A
Terminated NCT01712087 - Long-term Surveillance of the MedStream Programmable Infusion System
Completed NCT03906305 - Dry Needling and Bobath Treatment Clinical Effects Focused on Stroke Patients N/A
Completed NCT03302741 - Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings Phase 4
Completed NCT02291159 - Effects of DNHS Technique in the Treatment of Upper Limb Spasticity and Function in Stroke N/A
Completed NCT01743651 - Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis Phase 3
Completed NCT01523210 - DTI Study of the Influence of Physiotherapy on Distribution of BoNT in Spastic Muscle N/A
Completed NCT02073513 - Kinesiotaping the Hand in Cerebral Palsy N/A
Completed NCT00607542 - Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity Phase 1/Phase 2
Completed NCT00702468 - Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Phase 3
Active, not recruiting NCT04815967 - Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2/Phase 3